institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 6 days ago • loading... • Updated 4 days ago

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

Rosen Law Firm filed a class action lawsuit on behalf of purchasers of Capricor Therapeutics, Inc. securities from October 9, 2024, to July 10, 2025.
The lawsuit claims that Capricor misled investors about deramiocel, which is its therapy for cardiomyopathy linked to Duchenne muscular dystrophy, leading to inflated security prices.
Investors may seek compensation via a contingency fee arrangement without upfront costs and must file a motion by September 15, 2025.

Insights by Ground AI

Does this summary seem wrong?

24 Articles

24 Articles

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Capricor ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

4 days ago

Read Full Article

ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -

4 days ago·Denver, United States

Read Full Article

+20 Reposted by 20 other sources

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, July 21, 2025 /PRNewswire/ -

5 days ago

Read Full Article

Levi & Korsinsky Reminds Capricor Therapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025

Open the article to view the coverage from NewMediaWire

6 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Similar News Topics